Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,281 to 2,300 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Sepsis Transition and Recovery (STAR) Program vs Usual Care: Discharge to Hospice Care | 97 of 2,122 69 of 1,426 | -0.3 points -1.7 to 1.1 | 3,548 | NCT04495946 Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship |
| Sepsis Transition and Recovery (STAR) Program vs Usual Care: serious adverse events | 763 of 2,122 478 of 1,426 | 2.4 points -0.8 to 5.6 | 3,548 | NCT04495946 Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship |
| Vadadustat vs Darbepoetin Alfa: deaths from any cause | 276 of 1,768 290 of 1,769 | -0.8 points -3.2 to 1.6 | 3,537 | NCT02892149 Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD) |
| Vadadustat vs Darbepoetin Alfa: serious adverse events | 973 of 1,768 1,032 of 1,769 | -3.3 points -6.6 to -0.0 | 3,537 | NCT02892149 Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD) |
| Vacc-039 Group vs Vacc-092 Group: serious adverse events | 0 of 1,671 1 of 1,866 | -0.1 points -0.3 to 0.2 | 3,537 | NCT03629886 Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study |
| Semaglutide vs Placebo: Number of Participants From Time of Randomization to Occurrence of Initiation of Chronic Renal Replacement Therapy | 87 of 1,767 100 of 1,766 | -0.7 points -2.2 to 0.7 | 3,533 | NCT03819153 A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease |
| Semaglutide vs Placebo: Number of Participants From Time of Randomization to Time to First Occurrence of a Major Adverse Cardiovascular Event (MACE): Acute Myocardial Infarction (Non Fatal); Non-fatal Stroke; and CV Death | 212 of 1,767 254 of 1,766 | -2.4 points -4.6 to -0.2 | 3,533 | NCT03819153 A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease |
| Semaglutide vs Placebo: Number of Participants From Time of Randomization to Occurrence of CV Death | 123 of 1,767 169 of 1,766 | -2.6 points -4.4 to -0.8 | 3,533 | NCT03819153 A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease |
| Semaglutide vs Placebo: Number of Participants From Time of Randomization to Occurrence of Onset of Persistent ≥50% Reduction in eGFR (CKD-EPI) | 165 of 1,767 213 of 1,766 | -2.7 points -4.8 to -0.7 | 3,533 | NCT03819153 A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease |
| Semaglutide vs Placebo: Number of Participants From Time of Randomization to Time to First Occurrence of Major Adverse Limb Events (MALE): Acute Limb Ischaemia Hospitalization and Chronic Limb Ischaemia Hospitalization | 16 of 1,767 28 of 1,766 | -0.7 points -1.5 to 0.1 | 3,533 | NCT03819153 A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease |
| Semaglutide vs Placebo: Number of Participants From Time of Randomization to Occurrence of Renal Death | 5 of 1,767 5 of 1,766 | -0.0 points -0.4 to 0.4 | 3,533 | NCT03819153 A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease |
| Semaglutide vs Placebo: Number of Participants From Time of Randomization to Time to Occurrence of Each of the Individual Components of the Confirmatory Secondary MACE Endpoint: Non-fatal Myocardial Infarction | 52 of 1,767 64 of 1,766 | -0.7 points -1.9 to 0.5 | 3,533 | NCT03819153 A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease |
| Semaglutide vs Placebo: Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death | 331 of 1,767 410 of 1,766 | -4.5 points -7.2 to -1.8 | 3,533 | NCT03819153 A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease |
| Semaglutide vs Placebo: Number of Participants From Time of Randomization to Occurrence of Onset of Persistent eGFR (CKD-EPI) <15mL/Min/1.73m^2 | 92 of 1,767 110 of 1,766 | -1.0 points -2.6 to 0.5 | 3,533 | NCT03819153 A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease |
| Semaglutide vs Placebo: Number of Participants From Time of Randomization to Time to Occurrence of Each of the Individual Components of the Confirmatory Secondary MACE Endpoint: Non-fatal Stroke | 63 of 1,767 51 of 1,766 | 0.7 points -0.5 to 1.9 | 3,533 | NCT03819153 A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease |
| Semaglutide vs Placebo: Number of Participants From Time of Randomization to Time to Occurrence of All-cause Death | 227 of 1,767 279 of 1,766 | -3.0 points -5.3 to -0.6 | 3,533 | NCT03819153 A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease |
| Semaglutide vs Placebo: deaths from any cause | 227 of 1,767 279 of 1,766 | -3.0 points -5.3 to -0.6 | 3,533 | NCT03819153 A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease |
| Semaglutide vs Placebo: serious adverse events | 877 of 1,767 950 of 1,766 | -4.2 points -7.4 to -0.9 | 3,533 | NCT03819153 A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease |
| Intervention vs Control: deaths from any cause | 5 of 1,749 2 of 1,783 | 0.2 points -0.2 to 0.6 | 3,532 | NCT01849575 Visualization of Asymptomatic Atherosclerotic Disease for Optimum Cardiovascular Prevention |
| Novartis MenACWY Vaccine vs Licensed Meningococcal Vaccine: Number of Participants With at Least One Severe Systemic Reaction, Ages 11 to 55 Years | 94 of 2,649 24 of 875 | 0.8 points -0.6 to 2.0 | 3,524 | NCT00450437 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults |
Code
curl "https://conductscience.org/api/comparisons/v1?page=115"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=115
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT04495946-f32dda21",
"title": "Sepsis Transition and Recovery (STAR) Program vs Usual Care: Discharge to Hospice Care",
"summary": "97 of 2122 against 69 of 1426; risk difference -0.3 points, 95% interval -1.7 to 1.1; NCT04495946, Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship",
"record": "/library/comparisons/NCT04495946-f32dda21",
"nct_id": "NCT04495946",
"kind": "outcome",
"participants": 3548,
"risk_difference": {
"value": -0.0026755039372472686,
"lower": -0.017485557930330006,
"upper": 0.011264199868233559
},
"group_1": "97 of 2,122",
"group_2": "69 of 1,426",
"difference": "-0.3 points",
"interval": "-1.7 to 1.1",
"trial_title": "Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship"
},
{
"id": "NCT04495946-sae",
"title": "Sepsis Transition and Recovery (STAR) Program vs Usual Care: serious adverse events",
"summary": "763 of 2122 against 478 of 1426; risk difference 2.4 points, 95% interval -0.8 to 5.6; NCT04495946, Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship",
"record": "/library/comparisons/NCT04495946-sae",
"nct_id": "NCT04495946",
"kind": "serious-adverse-events",
"participants": 3548,
"risk_difference": {
"value": 0.02436308068944454,
"lower": -0.007678324573120655,
"upper": 0.05604934806473098
},
"group_1": "763 of 2,122",
"group_2": "478 of 1,426",
"difference": "2.4 points",
"interval": "-0.8 to 5.6",
"trial_title": "Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=116",
"request_id": "Ow4CoLdz83XFdjjT"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant